Separation Systems for Commercial Biotechnology Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The separation systems for the commercial biotechnology market studied were projected to grow with a CAGR of 4.7% over the forecast period. The major factor attributing to the growth of the market is the increasing advancement of cell separations and increasing demand for biopharmaceuticals. Opportunities in biopharmaceuticals have been increasing over the past decade, as a result of great effectiveness and the safety of these drugs. Biopharmaceuticals have also reduced the number of deaths caused due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market. Pulmozyme, a recombinant enzyme, is used to treat patients of cystic fibrosis with free DNA in their lungs. Earlier, there was no treatment other than manually pounding the patient’s chest. However, with the help of Pulmozyme, the patient was allowed to dislodge the free DNA from the lungs, which is more effective and safe. Furthermore, increasing government and private funding of the biotechnology segment is further boosting the market growth. However, the high cost of the research and development and patent rights over the MACS technique constraints the market growth.

Key Market Trends

Biopharmaceutical Segment is Dominating the Separation Systems for Commercial Biotechnology Market.

Increasing demand for personalized medicines and cell-based therapies coupled with a recent global shortage of vaccines are placing new demands on the segment, thus increasing the adoption of new technology-based systems for large-scale downstream bioprocessing. Pharmaceutical companies that have strong biopharmaceutical pipeline, is rendering the growth of these instruments for purification of biomolecules from debris during its large production. According to the report Biopharmaceutical benchmarks 2018, from 2014 - 2017, 155 biopharmaceutical products have been approved in the United States and/or European Union and globally, 2017 sales generated cumulatively by all biosimilar reference products reached USD 73.3 billion. Furthermore, the increasing funding by the government and major players on the research and development is propelling the segment growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the presence of key players, established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In this region, the United States has the maximum share due to supportive funding policies, and a developed healthcare market.

Competitive Landscape

The Separation Systems for Commercial Biotechnology market is moderately competitive and consists of several major players. Currently, major players are founding strategic partnerships with other entities and collaborating to enhance their product portfolios in the field of separation systems to develop technologically advanced systems. Some of the companies which are currently dominating the market are Perkin Elmer, Inc., Sartorius AG, Thermo Fisher Scientific, Inc., Merck KGaA, Becton, Dickinson and Company, Shimadzu Corporation, bioMérieux SA, Agilent Technologies, Bio-Rad Laboratories, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support